NCT07365410 2026-01-26
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
Tianjin Medical University Cancer Institute and Hospital
University of Pittsburgh
St. Jude Children's Research Hospital
University of Kentucky
Sun Yat-sen University
Fundación GECP